[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100623539":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":30,"locations":36,"responsibleParty":51,"collaborators":26,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":26,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":26,"enrollmentInfo":64,"targetDuration":26,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":26,"overallStatus":74,"whyStopped":26,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Samsung Medical Center","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Rebamipide Group","EXPERIMENTAL","Participants receive topical rebamipide 2% ophthalmic solution administered four times daily to the surgical eye, starting 1 month before cataract surgery and continuing for 3 months postoperatively.",[13],"Drug: Rebamipide 2% ophthalmic solution",{"label":15,"type":16,"description":17,"interventionNames":18},"Diquafosol Group","ACTIVE_COMPARATOR","Participants receive topical diquafosol 3% ophthalmic solution administered four times daily to the surgical eye, starting 1 month before cataract surgery and continuing for 3 months postoperatively.",[19],"Drug: Diquafosol 3% ophthalmic solution",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Rebamipide 2% ophthalmic solution","Topical administration to the surgical eye, four times daily.",[9],null,{"type":22,"name":28,"description":24,"armGroupLabels":29,"otherNames":26},"Diquafosol 3% ophthalmic solution",[15],[31],{"name":32,"role":33,"phone":34,"phoneExt":26,"email":35},"Dong-Hui Lim, MD, PhD","CONTACT","+82 2-3410-5478","ldhlse@gmail.com",[37],{"facility":38,"status":26,"city":39,"state":39,"zip":26,"country":40,"countryCode":26,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Samsung Mec","Seoul","South Korea",{"type":42,"coordinates":43},"Point",[44,45],126.9784,37.566,{"lat":45,"lon":44},[48],{"name":49,"role":33,"phone":50,"phoneExt":26,"email":35},"Dong-Hui Lim","+82 2 3410 5478",{"type":52,"investigatorFullName":53,"investigatorTitle":54,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Dong Hui Lim","Associate Professor","100623539","phase-4-rebamipide-versus-diquafosol-for-perioperative-dry-eye-in-cataract-surgery-100623539",false,"NCT07397949","Rebamipide Versus Diquafosol for Perioperative Dry Eye in Cataract Surgery","A Randomized Noninferiority Trial Comparing Rebamipide and Diquafosol for Perioperative Dry Eye Management in Cataract Surgery","Inclusion Criteria:\n\n* Adults aged 40 years or older scheduled for unilateral cataract surgery\n* Presence of dry eye disease, defined by an Ocular Surface Disease Index (OSDI) score ≥12 and at least one of the following:\n\n  * Tear film breakup time (TBUT) ≤7 seconds\n  * Oxford corneal staining grade ≥1\n  * Schirmer's test value ≤10 mm\u002F5 minutes\n* Ability and willingness to comply with the study protocol and follow-up schedule\n* Provision of written informed consent\n\nExclusion Criteria:\n\n* Active ocular infection or inflammation, including infectious keratitis\n* History of ocular surgery other than cataract surgery in the study eye\n* Use of topical medications that may affect the ocular surface (e.g., intraocular pressure-lowering eye drops)\n* Any ocular or systemic condition judged by the investigator to interfere with study participation or outcome assessment","ALL","40 Years",{"count":65,"type":66},60,"ESTIMATED","INTERVENTIONAL",[69],"PHASE4","This clinical trial is designed to compare two commonly used eye drop treatments for dry eye disease in patients undergoing cataract surgery.\n\nDry eye disease is common in people who need cataract surgery and may worsen before or after surgery, causing eye discomfort, blurred vision, and unstable vision. Proper management of dry eye before and after surgery may help improve eye comfort and the accuracy of vision outcomes.\n\nIn this study, patients with mild to moderate dry eye disease who are scheduled for cataract surgery will be randomly assigned to receive one of two treatments:\n\nRebamipide eye drops, or\n\nDiquafosol eye drops\n\nParticipants will begin using the assigned eye drops one month before cataract surgery and continue treatment for three months after surgery. The eye drops will be used only in the eye undergoing surgery.\n\nResearchers will examine whether one treatment is as effective as the other in improving tear film stability and reducing dry eye symptoms around the time of cataract surgery. Eye examinations and questionnaires will be performed before surgery, on the day of surgery, and during follow-up visits after surgery.\n\nThe information gained from this study may help doctors choose the most appropriate treatment for managing dry eye disease in patients undergoing cataract surgery.",[72,73],"Dry Eye Disease (DED)","Cataract","NOT_YET_RECRUITING","2026-02-02",{"date":77,"type":78},"2026-02-09","ACTUAL",{"date":80,"type":66},"2026-03",{"date":82,"type":66},"2027-03",{"name":5,"class":6},1]